TG23
General Information
DCTPep ID DCTPep01830
Peptide Name TG23
Sequence TAGIKLTVPIEKFPVTTQTFWG
Sequence Length 22
UniProt ID Not available
PubChem CID Not available
Origin Derived from the SAG1 surface protein from the parasite Toxoplasma gondii
Type Synthetic peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
COLO 205 | Colon adenocarcinoma | ~10% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | ~15% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | ~15% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
HTB-9(5637) | Bladder carcinoma | ~15% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | ~20% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
UM-UC-3 | Bladder carcinoma | ~25% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
UM-UC-3 | Bladder carcinoma | ~25% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
UM-UC-3 | Bladder carcinoma | ~25% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | ~40% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
UM-UC-3 | Bladder carcinoma | ~45% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | ~5% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
HCT 116 | Colon carcinoma | ~5% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
HCT 116 | Colon carcinoma | <15% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
HTB-9(5637) | Bladder carcinoma | <15% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | <3% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | <3% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
HTB-9(5637) | Bladder carcinoma | <3% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
UM-UC-3 | Bladder carcinoma | <45% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
COLO 205 | Colon adenocarcinoma | <5% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
HCT 116 | Colon carcinoma | <5% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
HTB-9(5637) | Bladder carcinoma | <5% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
HTB-9(5637) | Bladder carcinoma | <5% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
COLO 205 | Colon adenocarcinoma | <5% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
HCT 116 | Colon carcinoma | <5% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
HCT 116 | Colon carcinoma | <5% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
HTB-9(5637) | Bladder carcinoma | <5% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
COLO 205 | Colon adenocarcinoma | >10% cytotoxicity at 1 µM | MTT assay | 72 h | Patent |
COLO 205 | Colon adenocarcinoma | >10% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | >10% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | >20% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | >20% cytotoxicity at 10 µM | MTT assay | 72 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | >20% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
UM-UC-3 | Bladder carcinoma | >25% cytotoxicity at 10 µM | MTT assay | 48 h | Patent |
COLO 205 | Colon adenocarcinoma | 10% cytotoxicity at 1 µM | MTT assay | 48 h | Patent |
HCT 116 | Colon carcinoma | 15% cytotoxicity at 10 µM | MTT assay | 24 h | Patent |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | 5% cytotoxicity at 1 µM | MTT assay | 24 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep01830
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C116H180N26O31
Absent amino acids CDHMNRSY
Theoretical pI 8.26
Acidic residues 1
Basic residues 2
Polar residues 7
Molecular weight (Average) 2434.86
Molecular weight (Monoisotopic) 2433.33
Common amino acids T
Net charge 1
Instability index (II) 37.81
Aliphatic index 84.09
Grand average of hydropathicity (GRAVY) 0.245
Half Life
7.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 5500
Abs 0.1% (=1 g/l) 2.259
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID WO2012042540A2
Patent Title Anticancer Agent
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: JP, US, WO, EP; Legal Status: Pending; Application No: 2011000680; Filed: Sep 30, 2011; Published: Apr 5, 2012; Earliest Priority: Oct 1, 2010
Other Published ID WO2012042540A9 EP2621510A2 EP2621510A4 JP2013543493A JP5873499B2 US2014051643A1 US9624277B2